High-Resolution Bioactivity Profiling of Mixtures toward the Acetylcholine Binding Protein Using a Nanofractionation Spotter Technology

Abstract

This study describes the evaluation, validation, and use of contactless postcolumn fractionation of bioactive mixtures with acetylcholine binding protein (AChBP) affinity analysis with help of a spotter technology. The high-resolution fractionation tailors the fractionation frequency to the chromatographic peaks. Postcolumn reagents for AChBP bioaffinity profiling are mixed prior to droplet ejection into 1536-well plates. After an incubation step, microplate reader analysis is used to determine bioactive compounds in a mixture. For ligands tested, a good correlation was found for IC₅₀s determined in flow injection analysis mode when compared with traditional radioligand binding assays. After the evaluation and validation, bioaffinity profiling of actual mixtures was performed. The advantage of this “atline” technology using postcolumn bioaffinity analysis when compared to continuous flow online postcolumn bioaffinity profiling is the possibility to choose postcolumn incubation times freely without compromising resolution due to diffusion effects.

Keywords

contactless postcolumn HPLC spotter acetylcholine binding protein bioaffinity nanofractionation bioactive mixtures

Introduction

Traditionally, bioactive mixtures are fractionated prior to offline bioactivity profiling. One can think of natural extracts^1,2 and metabolic mixtures³ in which the fractionation process is followed by reconcentration, addition of biochemical reagents, incubation, and finally microplate reader analysis. Analysis of bioactives in mixtures is important in, for example, the pharmaceutical area to assess their medicinal and/or ADME(T) potential. Here, one can think of metabolic mixtures or compound screening libraries with impurities. Moreover, in environmental analysis, pollutants with adverse bioactivities (e.g., endocrine disruptors) have to be identified. Here, problems arise as the high-resolution chromatographic separation employed is succeeded by a usually low-resolution fractionation process and consequently low-resolution bioactivity profiling.⁴ In some cases, the postcolumn biochemical microplate reader assays can be transformed into online continuous flow assays.⁵ For this, the bioassay to be used must have a short incubation time and a relatively high target protein concentration, and the target protein has to be relatively stable. Furthermore, a good, preferably fluorescence-based, assay window has to be reached within the short postcolumn incubation times.^6,7 As a consequence, many assay formats are out of reach, and thus one has to revert back to fractionation strategies. Recently, we demonstrated high-resolution fractionation strategies in which many more microfractions can be collected at shorter time intervals for bioaffinity analysis, thus maintaining the high resolution obtained during the separation. These fractions were collected into 1536-well microplates in which biochemical assay reagents were simultaneously mixed in.⁸ Follow-up work allowed contactless fractionation in the same high-resolution format for further offline analysis.⁹ The advantage of this improvement is the capability of handling lower flow rates (nL/min range), thereby enabling the use of lower well volumes and faster fractionation when desired. This spotting technology is based on the rapid clamping of a flexible section in a flow-through tubing, which results in the ejection of a droplet on demand. These droplets can then be collected directly into wells of a high-density (1536) microplate compatible with microplate-based follow-up biochemical analyses.

We now describe the evaluation, validation, and use of contactless postcolumn fractionation of bioactive mixtures with acetylcholine binding protein (AChBP)¹⁰ affinity analysis with help of this spotter technology. AChBP is a structural analogue of the extracellular ligand-binding domain of nicotinic acetylcholine receptors (nAChRs) that constitute potential pharmaceutical targets against pain relief, Alzheimer disease, Parkinson disease, epilepsy, anxiety, and several cognitive and attention deficits.^11–15 AChBP displays comparable ligand pharmacology to the α7 nAChR in particular^14,15 and originates from mollusks. Since the first crystal structure was published in 2001,¹⁶ it has become a target to identify novel ligands for nAChRs. We chose to use the AChBP biochemical assay format in the high-resolution spotted offline mode instead of the recently described online format¹⁰ because the offline format has the capability of identifying compounds with slow binding kinetics (e.g., a low k_on), which rely upon and necessitate long incubation times for binding.

The setup as shown in Figure 1 was used where the biochemical AChBP assay constituents were directed into the spotter via 2 prespotter connected superloops. For this, the LC eluent was mixed with AChBP and tracer ligand DAHBA (based on fluorescence enhancement) prior to spotting into a 1536-well microtiter format for subsequent biochemical affinity plate reader readout. Parallel MS detection was performed for identification of bioactive compounds in mixtures.

Fig. 1.

Schematic view of the setup. High-performance liquid chromatography (HPLC) pump C and D provide a gradient LC separation followed by a split to MS and the postcolumn contactless spotter technology. The spotter heart mixes acetylcholine binding protein (AChBP) and tracer ligand DAHBA and provides the pulses (via a rapid hammering device) for the actual spotting process. For the spotting process, the mixed-in DAHBA and AChBP (housed in superloop 1 and 2, respectively, and operated by HPLC pump A and B) are pulsed into the spotter head, where they are mixed in with LC eluent and subsequently spotted via the spotter end tip into a 1536-well plate. After incubation, a plate reader is used for bioaffinity analysis. AI = autoinjector.

Materials and Methods

Chemicals and reagents

The ligands (1) VUF10537, (2) VUF10536, (3) VUF10942, (4) VUF10541, (5) VUF10539, (6) VUF10663, (7) VUF10751, (8) VUF10709, (9) VUF10710, and (10) VUF10737 were used for this study. The chemical structures of these ligands, including nicotine and epibatidine, are given in Figure 2 . All ligand stock solutions were made in DMSO (^10–2M) and stored at -80 °C. The mixture analyzed contained the compounds 6, 7, 8, 9, and 10 in a concentration of 20 µM in 10% methanol (MeOH)/90% water (v/v). Acetonitrile (high-performance liquid chromatography [HPLC] grade), S-nicotine, epibatidine, α-bungarotoxin (batch no. 017K4062 and 056K4113) were from Sigma Aldrich (Zwijndrecht, the Netherlands). Fluorescein and DMSO were purchased from Riedel-de Haën (Seelze, Germany). The synthetic route to 5-(diethylamino)-2-((2-(pyridin-3-yl)-5,6-dihydropyridin-3(4H)-ylidene)methyl)phenol (tracer ligand DAHBA) is described by Kool et al.¹⁰ Enzyme-linked immunosorbent assay (ELISA) blocking reagent (ELISA BR) was from Hoffmann-La Roche (Mannheim, Germany). MeOH (HPLC grade) was from Biosolve (Valkenswaard, the Netherlands), and formic acid was from Merck (Zwijndrecht, the Netherlands).

Fig. 2.

Structures of the ligands used for the study. (1) VUF10537, (2) VUF10536, (3) VUF10942, (4) VUF10541, (5) VUF10539, (6) VUF 10663, (7) VUF10751, (8) VUF10709, (9) VUF10710, (10) VUF10737, (11) nicotine, (12) epibatidine.

Biochemical assay

Baculovirus with the pFastbac I vector in Sf9 insect cells was used for expressing the Ls-acetylcholine binding protein (AChBP; from snail species Lymnaea stagnalis). Expression and purification from the medium is described by Celie et al.¹⁵ The assay is based on the competition of ligands with the tracer ligand DAHBA, which has an increased fluorescence yield in the active site of AChBP.¹⁰ The following TRIS/PBS buffer was used: 1 mM KH₂PO₄, 3 mM Na₂HPO₄, 0.16 mM NaCl, and 20 mM Trizma-base at pH 7.5 with 400 mg/L ELISA BR. For operation of the superloops (10 mL in-house–built superloops) delivering the biochemical assay constituents (AChBP and tracer ligand DAHBA), two Shimadzu LC10ADvp pumps (50 µL/min) were used, resulting in continuous delivery of 6.6 nM AChBP (lower superloop) and 150 nM DAHBA (upper superloop) to an inverted Y-shaped mixing piece prior to coupling to the spotter heart. The superloops were kept on ice and operated at a flow rate of 50 µL/min. The LC eluent was postcolumn mixed with the biochemical assay constituents during the spotting process in the black, flat-bottomed 1536-well plates from Brand (Wertheim, Germany). This gave a ratio of postcolumn eluent to assay components of 1:8 in every collected fraction. Incubation of the plates was subsequently done at 4 °C in the dark for 3 h before plate reader analysis with a Victor3 1420 multilabel counter (Perkin Elmer, Wallac, Oy, Finland). As readout time per well, 0.1 s with excitation and emission filters of 485 nm and 535 nm, respectively, were used. The signals recorded from all wells were finally used for construction of bioaffinity chromatograms in Excel.

Apparatus

Spotter

A detailed description of the spotter technology and connection to the whole setup is given by Kool et al.⁹ In short, the key of the spotter technology is the hitting of a flexible section in flow-through tubing by a rod-shaped hammering device positioned in the magnetic switch part of a solenoid valve. The size/volume of the ejected droplets is controlled by the hammering frequency and the inner diameter of the spotter outlet tube (PEEK or fused silica). The spotter head is fitted to the robotic arm (at the Z-stage) of a modified Gilson 234 autoinjector (Middleton, WI). Here, the spotter was operated at a droplet ejection frequency of 3 Hz with ˜0.5 µL per droplet ejected with fractions of 2 s, thus having six droplets (3 µL) spotted per well.

Spotter performance with 1536-well microtiter plates

For evaluating the performance and repeatability of the spotting process in 1536-well microtiter plates, in comparison to the performance and repeatability of the actual plate reader analysis, three different experiments were conducted. For this, 30 nM fluorescein in phosphate buffer (100 mM; pH 7.4) was used. First, the fluorescein solution was directly spotted onto 1536-well microtiter plates using the setup ( Fig. 1 ) in eluent infusion mode (without the LC column) and operating only one superloop with the fluorescein solution. Second, 1536-well microtiter plates were filled by using a contact-based flow-fractionation approach similar to the one described by Giera et al.⁸ also in the eluent infusion mode. Third, 1536-well plates were filled by submersion in the fluorescein solution under vacuum followed by a 1 min centrifugation step at 1000 rpm of the 1536-well microtiter plates. After the three different well plate preparation processes, all plates were analyzed with a microplate reader to evaluate the differences in fluorescence per well and corresponding standard deviations.

Mass spectrometry

A Bruker micrOTOF-Q instrument (Bruker Daltonics, Bremen, Germany) equipped with an electrospray ionization source was used in the positive-ion mode. The specific MS operating conditions were the same as described previously.⁹

Liquid chromatography

For operation in gradient LC mode (with two Shimadzu LC-10ADvp pumps; Shimadzu, Hertogenbosch, the Netherlands), a Waters Xterra MS C₁₈ column (2.1 × 100 mm, 3.5 µm particles; Milford, MA) with guard column was used with a flow rate of 125 µL/min. Mobile phase A consisted of H₂O-MeOH-formic acid (98.9%-1%-0.1% [v/v/v]) and mobile phase B of H₂O-MeOH-formic acid (1%-98.9%-0.1% [v/v/v]). The gradient used was 6 min at 0% mobile phase B followed by a linear increase to 100% mobile phase B in 35 min followed by 2 min at 100% mobile phase B. Equilibration occurred by performing a linear decrease to the starting conditions in 1 min followed by 4 min of re-equilibration time. After the LC column, a 1:9 splitting of the flow to the biochemical assay and MS, respectively, was applied. The resulting amount of organic modifier entering the bioassay during the whole gradient did not significantly influence the bioassay (data not shown.)

Results and Discussion

This article describes the use of a postcolumn contactless spotting technology for high-resolution fractionation of LC eluents into 1536-well plates, enabling incubation with the AChBP and bioaffinity assessment. The methodology allows simultaneous identity profiling by MS and parallel high-resolution bioaffinity assessment of the collected fractions (2 s per fraction) after LC separation. In this way, individual bioactive compounds can be identified in mixtures as such together with a simultaneous MS-based chemical identification. Prior to fractionation, the necessary biochemical reagents are mixed with the LC eluent. Multiple droplets were spotted into each well of a microtiter plate, allowing for control of the total volume per well (six droplets, corresponding to 2-s fractions). After spotting and mixing of biochemical reagents, any incubation time of choice can be chosen as necessary to reach equilibrium or the desired signal prior to the microplate reader analysis. The reconstructed bioaffinity chromatograms are correlated to the parallel measured MS data in order to identify the bioactive compounds in the mixtures analysed. First, the spotting repeatability and microplate reader repeatability in combination with 1536-well plates were evaluated chemically using fluorescein. Then, the evaluation, validation, and actual high-resolution bioactivity profiling of pure compounds as well as mixtures toward AChBP by the nanofractionation spotter technology were performed.

Evaluation of the spotting repeatability in 1536-well microtiter format

To evaluate the repeatability of the spotting process in 1536-well format, 1536-well plates were filled with fluorescein (30 nM) in phosphate buffer (100 mM, pH 7.4) in three different ways followed by plate reader analysis. Initially, this was done by a flow-fractionation approach in which the end-tip of the spotter made contact with every well during the fractionation process. This setup was similar to a contact-based fractionation device,⁸ operated in eluent infusion mode (without the LC column). The second approach comprised submersion of 1536-well microtiter plates in the same buffer with fluorescein under vacuum to ensure that all wells were completely filled. Subsequently, the microtiter well plates were centrifuged prior to the plate reader analysis. In this case, the fluorescein concentration in every well should be exactly the same, thus allowing evaluation of the efficiency of the plate reader only. The third approach consisted of using the current spotter setup, in the eluent infusion mode, with only one superloop operating and delivering the fluorescent solution. This is to spot the buffer with the fluorescein into the 1536-well microtiter plates. In the supplemental data, Figure S-1A shows superimposed (with offsets to improve clarity) reconstructed chromatograms resulting from the plate reader analyses. The reconstructed chromatograms were produced by plotting the plate reader readout from every well against the time of fractionation per well in Excel in an X,Y scatter graph. All chromatograms showed approximately the same average fluorescence measured before superimposing them. The lowest chromatogram represents the actual average fluorescence measured relative to zero, whereas the others are thus superimposed. As can be deduced from this figure, in all three situations, measured in duplicate, approximately the same repeatability was observed. Most of the observed scatter can thus be attributed to the plate reader analysis of the 1536-well plates and not to the spotting process. This hypothesis is strengthened by the fact that much better repeatabilities were obtained with the spotting process in 96-well microtiter format (data not shown). Another observation is the baseline fluctuation of the chromatograms. It was found that the fluctuations had a regular pattern comprising 48 wells per fluctuation. This was caused by the 1536-well microtiter plates in which each row consists of 48 wells. These 48-well pattern regular fluctuations can be normalized de novo in Excel by subtracting the fluctuating pattern of the chromatograms measured. The resulting chromatograms after this procedure can be found in the supplemental data in Figure S-1B.

Evaluation, validation, and actual high-resolution bioactivity profiling of pure compounds and mixtures on the AChBP aided by the nanofractionation spotter technology

The reason for using the AChBP biochemical assay format in this offline mode rather than the recently described online format¹⁰ is the capability of the offline format to identify compounds with slow binding kinetics, which require long incubation times for binding equilibrium to be reached. Efficient measurement of these types of compounds, such as α-bungarotoxin,¹⁷ a peptidic antagonist of the α7 nAChR with a molecular weight of ˜8000 Da, is not possible with the online format. Because biochemical assay development of the fluorescence enhancement–based AChBP bioassay was already known,¹⁰ we used these optimized biochemical assay conditions for direct transfer to the offline biochemical assay for this work.

First, different test ligands were injected in the flow injection analysis mode in a serially diluted fashion. The chemical structures of these ligands are presented in Figure 2 . Ligands 1 to 5 are known α7 nAChR ligands that were synthesized in house and were shown to have high affinities for AChBP. Ligands 6 to 10 result from an in-house fragment optimization project on AChBP. After the eluent was mixed in with the biochemical assay and spotted into 1536-well microtiter plates, an incubation of 3 h was allowed. Then, the fluorescence response in every well was determined, and individual well-based fluorescence responses indicative of bioaffinities were plotted in time to construct bioaffinity chromatograms. This resulted in high-resolution bioaffinity chromatograms comparable with traditional online HRS bioaffinity traces^18,19 but with the possibility of using biochemical assays with long incubation times. A typical result from four different ligands injected in triplicate at each concentration can be found in the supplemental data in Figure S-2. The sequence for ligand VUF10539 (5) was performed three times to demonstrate the repeatability during measuring days. Negative peak heights were subsequently plotted against the compound concentration in the biochemical assay to construct IC₅₀ curves. For determination of the actual concentration of ligand present in the biochemical assay format after injection, a dilution factor was determined to compensate for dilution in the system after injection. The dilution factor was determined in the same way as described before,²⁰ only now with the readout in the offline manner. The dilution factor was found to be 24.8 ± 1.1 and comprised dilution effects from both the LC separation and the necessary dilution steps that occur during the postcolumn mixing in of the biochemical assay reagents. For 12 different compounds, IC₅₀s were measured (of which seven typical IC₅₀ curves are shown in Fig. 3A ). Furthermore, for the compounds VUF10537 (1), VUF10539 (5), and bungarotoxin, full IC₅₀ curves (in triplicate) were measured repeatedly over different measurement days. The corresponding IC₅₀ values of all compounds analyzed are shown in Table 1 . When plotting the IC₅₀ values found with pK_is calculated from a traditional radioligand binding assay, a good correlation of r² = 0.913 was obtained (see Fig. 3B ). This proves that the proposed technology gives similar results to the ones obtained with traditional methodologies. Even for bungarotoxin, with slow binding kinetics, the correlation with the traditional radioligand binding assay was good as the binding equilibrium could be established in the time frame of the postcolumn incubation (3 h in this case). When the affinity for the slow k_on kinetics bungarotoxin was determined with the previously described online technology,¹⁰ a more than 50 times lower affinity was found. Bioaffinity analysis of compounds with slow k_on kinetics can thus be done in this postcolumn fashion because long postcolumn incubation times (3 h in this case) can be used. Furthermore, the technology is expected to be applicable for bioaffinity analysis using bioassays with long incubation times in general. For endpoint enzymatic assays, each measurement has to be obtained at an exact development time. For this, the plate reader has to read the wells in the same time frame as the fractionation speed (2 s in our case) and following the same readout path for the wells as the fractionation path (we used a serpentine fractionation pattern, for example). In receptor binding assays, this is less of an issue.

Table 1.

Bioaffinities Analyzed from the Plate Reader Readout–Based Bioaffinity Chromatograms Resulting from the Online Spotted Postcolumn Biochemical Assay

Compound	RBA (IC₅₀)	Offline Spotter (IC₅₀)
VUF10536 (2)	7.21	6.92
VUF10537 (1)	6.25	6.69
		6.14
VUF10539 (5)	7.74	7.35
		7.28
		7.13
		7.44
VUF10541 (4)	7.05	6.99
VUF10663 (6)	6.66	6.76
VUF10709 (8)	7.61	7.41
VUF10710 (9)	6.59	6.75
VUF10737 (10)	7.59	7.43
VUF10751 (7)	6.29	6.43
VUF10942 (3)	7.84	7.24
Nicotine	6.00	6.28
Bungarotoxin	8.59^a	7.91
		8.04
Epibatidine	9.00	7.82

Ligands were introduced via the spotter technology in flow injection analysis mode. For this, ligands were serially diluted and injected in triplicate. Bioaffinities of the ligands measured with a traditional radioligand binding assay (RBA) are also depicted in the table for comparison.

Affinity determined by Smit et al.²¹

Fig. 3.

(A) IC₅₀ curves of different acetylcholine binding protein (AChBP) ligands. The spotter technology also allows efficient bioaffinity analysis of compounds with a low k_on due to the possibility of long 1536-well microtiter plate–based incubation times. (B) Correlation of affinities from the offline bioaffinity analysis system and a traditional radioligand binding assay. For comparison, IC₅₀ values were measured for 12 different compounds of which for some, multiple IC₅₀ curves were measured during different days.

For the actual postcolumn hyphenation process, the spotter technology was coupled to gradient reversed-phase LC and in parallel with MS ( Fig. 1 ) to allow mixture analysis. In Figure 4 , the lower two (reconstructed) chromatograms represent the bioaffinity trace of a mixture (2 and 10 µL injected, respectively) and the upper chromatogram the MS trace measured in parallel. The figure shows that efficient and correlated high-resolution bioaffinity analysis toward AChBP is possible, employing long incubation times, with parallel MS for compound identification. This implies that the technology is thus applicable for bioaffinity analysis of ligands with slow binding kinetics in mixtures. The discrete well-based fractionation allowed us to freely choose postcolumn incubation times without compromising resolution.

Fig. 4.

The two lower chromatograms (13–23 min of the total chromatograms are shown) represent the bioaffinity traces of a mixture injected with two different injection volumes (2 µL and 10 µL). The upper trace is the parallel MS trace (from 10 µL injected).

Footnotes

Acknowledgements

August B. Smit, Gerdien de Kloe, Ewald Edink, and Iwan J. P. de Esch received funds from TI-Pharma project D2-103.

Supplementary material for this article is available on the Journal of Biomolecular Screening Web site at .

References

Park

J. S.

Paredes

Song

M. C.

Baek

N. I.

Lee

S. I.

Lim

J. S.

Cho

N. Y.

Yoon

Baek

Screening and Isolation of a Natural Dopamine D1 receptor antagonist using cell-based assays. J. Biotechnol. 2010, 145, 304–309.

Nyila

M. A.

Leonard

C. M.

Hussein

A. A.

Lall

Bioactivities of Plectranthus ecklonii Constituents. Nat. Prod. Commun. 2009, 4, 1177–1180.

Ebada

S. S.

Edrada

R. A.

Lin

Proksch

Methods for Isolation, Purification and Structural Elucidation of Bioactive Secondary Metabolites from Marine Invertebrates. Nat. Protoc. 2008, 3, 1820–1831.

Tammela

Wennberg

Vuorela

HPLC Micro-Fractionation Coupled to a Cell-Based Assay for Automated On-line Primary Screening of Calcium Antagonistic Components in Plant Extracts. Anal. Bioanal. Chem. 2004, 380, 614–618.

Kool

Giera

Irth

Niessen

W. M.

Advances in Mass Spectrometry–Based Post-column Bioaffinity Profiling of Mixtures. Anal. Bioanal. Chem. 2011, 399, 2655–2668.

Kool

van Liempd

S. M.

Harmsen

Beckman

van Elswijk

Commandeur

J. N.

Irth

Vermeulen

N. P.

Cytochrome P450 Bio-affinity Detection Coupled to Gradient HPLC: On-line Screening of Affinities to Cytochrome P4501A2 and 2D6. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2007, 858, 49–58.

Reinen

Kool

Vermeulen

N. P.

Reversed-Phase Liquid Chromatography Coupled On-line to Estrogen Receptor Bioaffinity Detection Based on Fluorescence Polarization. Anal. Bioanal. Chem. 2008, 390, 1987–1998.

Giera

Heus

Janssen

Kool

Lingeman

Irth

Microfractionation Revisited: A 1536 Well High Resolution Screening Assay. Anal. Chem. 2009, 81, 5460–5466.

Kool

de Kloe

Denker

A. D.

van Altena

Smoluch

van Iperen

Nahar

T. T.

Limburg

R. J.

Niessen

W. M.

Lingeman

Leurs

de Esch

I. J.

Smit

A. B.

Irth

Nanofractionation Spotter Technology for Rapid Contactless and High-Resolution Deposition of LC Eluent for Further Off-line Analysis. Anal. Chem. 2011, 83, 125–132.

10.

Kool

de Kloe

G. E.

Bruyneel

de Vlieger

J. S.

Retra

Wijtmans

van Elk

Smit

A. B.

Leurs

Lingeman

de Esch

I. J.

Irth

Online Fluorescence Enhancement Assay for the Acetylcholine Binding Protein with Parallel Mass Spectrometric Identification. J. Med. Chem. 2010, 53, 4720–4730.

11.

Hogg

R. C.

Bertrand

Nicotinic Acetylcholine Receptors as Drug Targets. Curr. Drug Targets. CNS Neurol. Disord. 2004, 3, 123–130.

12.

Hogg

R. C.

Raggenbass

Bertrand

Nicotinic Acetylcholine Receptors: From Structure to Brain Function. Rev. Physiol. Biochem. Pharmacol. 2003, 147, 1–46.

13.

Dutertre

Ulens

Buttner

Fish

van Elk

Kendel

Hopping

Alewood

P. F.

Schroeder

Nicke

Smit

A. B.

Sixma

T. K.

Lewis

R. J.

AChBP-Targeted Alpha-Conotoxin Correlates Distinct Binding Orientations with nAChR Subtype Selectivity. EMBO. J. 2007, 26, 3858–3867.

14.

Smit

A. B.

Brejc

Syed

Sixma

T. K.

Structure and Function of AChBP, Homologue of the Ligand-Binding Domain of the Nicotinic Acetylcholine Receptor. Ann. N. Y. Acad. Sci. 2003, 998, 81–92.

15.

Celie

P. H.

Kasheverov

I. E.

Mordvintsev

D. Y.

Hogg

R. C.

van Nierop

van Elk

van Rossum-Fikkert

S. E.

Zhmak

M. N.

Bertrand

Tsetlin

Sixma

T. K.

Smit

A. B.

Crystal Structure of Nicotinic Acetylcholine Receptor Homolog AChBP in Complex with an Alpha-Conotoxin PnIA Variant. Nat. Struct. Mol. Biol. 2005, 12, 582–588.

16.

Brejc

van Dijk

W. J.

Klaassen

R. V.

Schuurmans

van Der Oost

Smit

A. B.

Sixma

T. K.

Crystal Structure of an ACh-Binding Protein Reveals the Ligand-Binding Domain of Nicotinic Receptors. Nature. 2001, 411, 269–276.

17.

Hansen

S. B.

Radic

Talley

T. T.

Molles

B. E.

Deerinck

Tsigelny

Taylor

Tryptophan Fluorescence Reveals Conformational Changes in the Acetylcholine Binding Protein. J. Biol. Chem. 2002, 277, 41299–41302.

18.

de Vlieger

J. S.

Kolkman

A. J.

Ampt

K. A.

Commandeur

J. N.

Vermeulen

N. P.

Kool

Wijmenga

S. S.

Niessen

W. M.

Irth

Honing

Determination and Identification of Estrogenic Compounds Generated with Biosynthetic Enzymes Using Hyphenated Screening Assays, High Resolution Mass Spectrometry and Off-line NMR. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci. 2010, 878, 667–674.

19.

Falck

de Vlieger

J. S.

Niessen

W. M.

Kool

Honing

Giera

Irth

Development of an Online p38alpha Mitogen-Activated Protein Kinase Binding Assay and Integration of LC-HR-MS. Anal. Bioanal. Chem. 2010, 398, 1771–1780.

20.

Kool

van Liempd

S. M.

Ramautar

Schenk

Meerman

J. H.

Irth

Commandeur

J. N.

Vermeulen

N. P.

Development of a Novel Cytochrome p450 Bioaffinity Detection System Coupled Online to Gradient Reversed-Phase High-Performance Liquid Chromatography. J. Biomol. Screen. 2005, 10, 427–436.

21.

Smit

A. B.

Syed

N. I.

Schaap

van Minnen

Klumperman

Kits

K. S.

Lodder

van der Schors

R. C.

van Elk

Sorgedrager

Brejc

Sixma

T. K.

Geraerts

W. P.

A Glia-Derived Acetylcholine-Binding Protein That Modulates Synaptic Transmission. Nature. 2001, 411, 261–268.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.16 MB